NASDAQ:PYXS

Pyxis Oncology Q4 2024 Earnings Results & Report

Pyxis Oncology logo
$1.44 +0.03 (+2.13%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$1.46 +0.02 (+1.53%)
As of 08:07 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pyxis Oncology beat analyst earnings expectations in its Q4 2024 results, released March 18, 2025. The company reported EPS of -$0.32 versus the -$0.33 consensus estimate, while revenue was $16.15 million.

Earnings Announcement Details

Quarter
Q4 2024
Report Date
Time
Before Market Opens
Conference Call
8:00 AM ET

Pyxis Oncology EPS Results

Actual EPS
-$0.32
Consensus EPS
-$0.33
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Pyxis Oncology Revenue Results

Actual Revenue
$16.15 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Pyxis Oncology Q4 2024 Earnings FAQ

Pyxis Oncology (NASDAQ:PYXS) reported earnings of -$0.32 per share for Q4 2024, beating the consensus estimate of -$0.33. The report was announced on Tuesday, March 18, 2025.

Pyxis Oncology reported revenue of $16.15 million for Q4 2024.

Pyxis Oncology Earnings Headlines

Pyxis Oncology (NASDAQ:PYXS) Upgraded at Wall Street Zen
Worse than socialism
Donald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same economic system, according to veteran analyst Porter Stansberry. The government has already taken stakes in companies like Intel, Lithium Americas, and MP Materials, while political rhetoric on both sides points toward deeper centralization. Stansberry has spent months investigating what this bipartisan shift could mean for investors navigating the months ahead.tc pixel
Pyxis Oncology (NASDAQ:PYXS) Price Target Raised to $7.00
See More Pyxis Oncology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Pyxis Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pyxis Oncology and other key companies, straight to your email.

About Pyxis Oncology

Pyxis Oncology (NASDAQ:PYXS) is a clinical-stage biotechnology company developing antibody-based medicines for people with difficult-to-treat cancers. Its research focuses on targeted therapies intended to attack tumors while limiting effects on healthy tissue.

The company’s pipeline includes PYX-201, an investigational antibody-drug conjugate designed to target EDB+ fibronectin, a protein found in the tumor microenvironment. The program reflects Pyxis Oncology’s broader approach of using antibodies to direct cancer-fighting agents to tumor-associated targets.

Founded in 2019 and based in Boston, Massachusetts, Pyxis Oncology was co-founded by Lara Sullivan, who has served as its president and chief executive officer. The company is focused on developing its therapies and does not have marketed products.

View Pyxis Oncology Profile